Hansoh Pharmaceutical Group Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Hansoh Pharmaceutical Group de 2.7% y 6.9% por año respectivamente. Se prevé que el BPA crezca en un 2.3% al año. Se espera que la rentabilidad financiera sea de 12.4% en 3 años.
Información clave
2.7%
Tasa de crecimiento de los beneficios
2.3%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 11.0% |
| Tasa de crecimiento de los ingresos | 6.9% |
| Rentabilidad financiera futura | 12.4% |
| Cobertura de analistas | Good |
| Última actualización | 04 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?
Nov 04
Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Aug 28Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now
Aug 07If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity
Jul 16Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Jun 24Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 06Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
May 23Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 01Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Mar 28There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump
Mar 04An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued
Feb 16Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly
Dec 08Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate
Oct 12Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's
Sep 14These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Sep 09Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 10These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Jun 11Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jan 23Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Dec 01Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price
Oct 19Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Aug 28An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued
Jun 09Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing
May 19Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?
Apr 22An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued
Feb 06Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 13,866 | 4,433 | 4,384 | 4,225 | 20 |
| 12/31/2025 | 12,367 | 3,899 | 3,826 | 3,944 | 23 |
| 12/31/2024 | 12,056 | 4,149 | 3,679 | 3,372 | 23 |
| 6/30/2024 | 12,098 | 4,714 | 4,137 | 4,653 | N/A |
| 3/31/2024 | 11,101 | 3,996 | 3,446 | 3,885 | N/A |
| 12/31/2023 | 10,104 | 3,278 | 2,754 | 3,116 | N/A |
| 9/30/2023 | 9,782 | 2,926 | 2,292 | 2,615 | N/A |
| 6/30/2023 | 9,459 | 2,575 | 1,830 | 2,114 | N/A |
| 3/31/2023 | 9,421 | 2,579 | 2,140 | 2,427 | N/A |
| 12/31/2022 | 9,382 | 2,584 | 2,449 | 2,741 | N/A |
| 9/30/2022 | 9,675 | 2,652 | 2,646 | 3,004 | N/A |
| 6/30/2022 | 9,968 | 2,720 | 2,842 | 3,267 | N/A |
| 3/31/2022 | 9,952 | 2,717 | 2,472 | 2,922 | N/A |
| 12/31/2021 | 9,935 | 2,713 | 2,102 | 2,577 | N/A |
| 9/30/2021 | 9,524 | 2,675 | 1,415 | 2,345 | N/A |
| 6/30/2021 | 9,112 | 2,638 | 729 | 2,113 | N/A |
| 3/31/2021 | 8,901 | 2,603 | 840 | 2,252 | N/A |
| 12/31/2020 | 8,690 | 2,569 | 951 | 2,390 | N/A |
| 9/30/2020 | 8,377 | 2,526 | 1,775 | 2,802 | N/A |
| 6/30/2020 | 8,063 | 2,483 | 2,600 | 3,213 | N/A |
| 3/31/2020 | 8,373 | 2,520 | 2,666 | 3,271 | N/A |
| 12/31/2019 | 8,683 | 2,557 | 2,732 | 3,330 | N/A |
| 9/30/2019 | 8,615 | 2,357 | 2,529 | 3,092 | N/A |
| 6/30/2019 | 8,548 | 2,157 | 2,325 | 2,854 | N/A |
| 3/31/2019 | 8,135 | 2,030 | 2,008 | 2,463 | N/A |
| 12/31/2018 | 7,722 | 1,903 | 1,690 | 2,072 | N/A |
| 12/31/2017 | 6,186 | 1,595 | N/A | 1,402 | N/A |
| 12/31/2016 | 5,433 | 1,476 | N/A | 1,247 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (2.7% al año) de 3692 es superior a la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Se prevé que los beneficios (2.7% al año) de 3692 crezcan menos que el mercado Hong Kong (11.6% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de 3692 crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (6.9% al año) de 3692 crezcan más despacio que el mercado de Hong Kong (7.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 6.9% al año) de 3692 crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de 3692 sea baja dentro de 3 años (12.4%).